Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | NOVO B:CPH since announced | Transaction value |
---|---|---|
Cardior Pharmaceuticals GmbH | 2.69% | 1.11bn |
Catalent Inc-Manufacturing Sites Portfolio(3) | 16.60% | -- |
Elan Drug Technologies (DNU>16Sep2011 now 01781A) | 35.62% | 92.42m |
Embark Biotech ApS | 40.93% | 16.22m |
Inversago Pharma Inc | 44.23% | 1.08bn |
Data delayed at least 15 minutes, as of May 21 2024 12:33 BST.